In a report released today, Robert Burns from H.C. Wainwright reiterated a Buy rating on Portage Biotech Inc (PRTG – Research Report), with a price target of $9.00. The company’s shares closed yesterday at $2.97.
Burns covers the Healthcare sector, focusing on stocks such as Replimune Group, BioNTech SE, and Viracta Therapeutics. According to TipRanks, Burns has an average return of -27.9% and a 21.84% success rate on recommended stocks.
Portage Biotech Inc has an analyst consensus of Moderate Buy, with a price target consensus of $9.00.
See today’s best-performing stocks on TipRanks >>
The company has a one-year high of $9.91 and a one-year low of $2.34. Currently, Portage Biotech Inc has an average volume of 16.89K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Portage Biotech, Inc. is engaged in researching & developing pharmaceutical and biotech products through to clinical proof of concept with an initial focus on unmet clinical needs and orphan drugs. It sells and licenses the products to large pharmaceutical companies for further development and commercialization. The company was founded in 1973 and is headquartered in Toronto, Canada.
Read More on PRTG:
- Portage Biotech Reports Fiscal Year-Ended March 31, 2023 Financial Results and Business Update
- Portage Biotech doses first patient in Phase 1a trial of PORT-6
- Portage Biotech Announces First Patient Dosed in Phase 1a Trial of PORT-6 in Select Solid Tumors
- Portage Biotech Reports Updated Interim Data for Lead iNKT Engager, PORT-2, in a Phase 1/2 Trial for the Treatment of Advanced Melanoma and Metastatic Non-Small Cell Lung Cancer at the 2023 American Society for Clinical Oncology (ASCO) Annual Meeting
